COMP <GO>
SION vs ADAG // EV/EBITDA & P/E VALUATION
Sionna Therapeutics Inc. (NASDAQ) VS. Adagene Inc. (NASDAQ) • 15-METRIC TALLY: SION 2
— ADAG 2
■ METRIC PARITY
LAST: $3.87 (-3.25%) • MKT CAP: $180.8M
valuation
—
LAST: $2.51 (-6.34%) • MKT CAP: $177.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SION VS. ADAG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SION | ADAG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.30% | -35.00% | +6.70 | SION | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -8.85% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 5/9 | -3.00 | ADAG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.4 | 43.5 | -14.09 | ADAG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $180.8M | $177.0M | $3.8M | SION | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SION REV | ADAG REV | SION GROSS % | ADAG GROSS % | SION FCF | ADAG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $7.7M | — | — | -$66.7M | -$15.7M |
| FY 2024 | $0 | $103.2K | — | — | -$52.8M | -$29.7M |
| FY 2023 | — | $18.1M | — | — | — | -$28.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SION // BETA —
ADAG // BETA —